April 2014
Volume 55, Issue 13
Free
ARVO Annual Meeting Abstract  |   April 2014
Proliferating Retinal Vascular Endothelial Cells are More Sensitive to Bevacizumab than Choroidal Vascular Endothelial Cells
Author Affiliations & Notes
  • Keyvan Koushan
    Ophthalmology, University of Florida, Jacksonville, Jacksonville, FL
  • Raluca Rusovici
    Ophthalmology, University of Florida, Jacksonville, Jacksonville, FL
  • K V Chalam
    Ophthalmology, University of Florida, Jacksonville, Jacksonville, FL
  • Footnotes
    Commercial Relationships Keyvan Koushan, None; Raluca Rusovici, None; K V Chalam, None
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science April 2014, Vol.55, 1944. doi:https://doi.org/
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Keyvan Koushan, Raluca Rusovici, K V Chalam; Proliferating Retinal Vascular Endothelial Cells are More Sensitive to Bevacizumab than Choroidal Vascular Endothelial Cells. Invest. Ophthalmol. Vis. Sci. 2014;55(13):1944. doi: https://doi.org/.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract
 
Purpose
 

To evaluate the effect of varying doses of bevacizumab on cell proliferation of vascular endothelial growth factor (VEGF)-enhanced choroidal vascular endothelial and retinal vascular endothelial cells. Even though bevacizumab has been used off-label for treatment of choroidal and retinal vascular diseases, the differential effect of this agent on choroidal and retinal endothelial cell proliferation has not been established.

 
Methods
 

Monkey choroidal endothelial RF/6A and human retinal endothelial cells were treated with escalating doses of both VEGF (0-400 ng/ml) and bevacizumab (0.1 to 2.0 mg/ml) for 48h, 72h and 1 week. Cell proliferation changes in response to bevacizumab were analyzed by the WST-1 and trypan blue exclusion assays. Morphological changes were recorded by bright field microscopy of cells.

 
Results
 

Cell proliferation analysis of VEGF-enriched CECs and RECs revealed that both cell lines respond to escalating doses of VEGF. Addition of escalating doses of bevacizumab (0.1 to 2.0 mg/ml) decreased CECs proliferation from 10.3% to 17.3% at 48 hours, from 2.35% to 23.7% at 72 hours, and from 4.1% to 17.7% at 1 week. RECs showed a more pronounced suppression of their proliferation in response to bevacizumab, especially at 72-hour and 1-week time points: Addition of escalating doses of bevacizumab (0.1 to 2.0 mg/ml) decreased RECs proliferation from 8.0 % to 23.9% at 48 hours, from -1.58 (non-significant increase) to 46.0% at 72 hours, and from 29.7% to 45.6% at 1 week.

 
Conclusions
 

Bevacizumab decreases proliferation of VEGF-enriched choroidal and retinal endothelial cells. This effect is especially pronounced on RECs and should be considered in dosage selection of this drug for treating retinal versus choroidal vascular diseases.

 
 
Decrease in Endothelial Cell Proliferation in at 72 hours in Response to Bevacizumab, Comparison between Retinal and Choroidal Endothelial Cells
 
Decrease in Endothelial Cell Proliferation in at 72 hours in Response to Bevacizumab, Comparison between Retinal and Choroidal Endothelial Cells
 
 
Decrease in Endothelial Cell Proliferation in 1 Week in Response to Bevacizumab, Comparison between Retinal and Choroidal Endothelial Cells
 
Decrease in Endothelial Cell Proliferation in 1 Week in Response to Bevacizumab, Comparison between Retinal and Choroidal Endothelial Cells
 
Keywords: 748 vascular endothelial growth factor • 654 proliferation • 700 retinal neovascularization  
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×